Key result
Transcutaneous pulmonary valve replacement significantly reduced the right ventricular outflow tract systolic gradient from 35.3 mm Hg to 13.5 mm Hg and restored valve competence.
Observational (n=46)
Yes
Answers are grounded in this paper and cite their sources.
Transcutaneous pulmonary valve replacement is a safe and effective procedure that significantly reduces RVOT gradients and defers surgical reintervention in patients with previous RVOT or PA surgical interventions.
BACKGROUND: Transcutaneous pulmonary valve replacement (TPVR) has become an alternative to heart surgery for patients after previous right ventricular outflow tract (RVOT) or pulmonary artery (PA) surgical interventions. The objective was to present immediate and long-term outcomes of trans¬cutaneous pulmonary valve replacement. METHODS: Between 06/2009 and 06/2016, 46 patients underwent TPVR. Initial diagnoses included tetralogy of Fallot, common arterial trunk, transposition of great arteries post Rastelli correction, left ventricle outflow obstruction after Ross operation, pulmonary atresia, and isolated dysplastic pulmonary valve stenosis. Thirty eight (78%) patients had previously implanted conduits in the pulmonary position, the rest had either RVOT patch reconstruction (n = 6; 13%) or biological valve implantation (n = 2; 4%). They presented primarily with pulmonary stenosis (n = 18; 39%) or regurgitation (n = 28; 60%). RESULTS: All procedures were successful - 44 Melody and 2 Edwards-Sapien valves were implanted. Before each procedure exclusion of potential coronary compression and RVOT prestenting was performed. Significant RVOT systolic gradient reduction (from 35.3 ± 19.5 to 13.5 ± 7.1 mm Hg; p < 0.001) and decrease of right to left ventricle systolic pressure ratio from 0.58 ± 0.18 to mean 0.37 ± 0.1 (p < 0.001) was achieved. Also, in every patient PA-RVOT competence was restored, with minor in¬competence in only a few patients. Post procedure follow-up ranged from 2 to 86 (mean 35.2) months. Follow-up fluoroscopy or chest X-ray revealed 6 stent fractures (2 stent defragmentation - with only 1 significant valve stenosis). CONCLUSIONS: Transcutaneous pulmonary valve replacement is a safe procedure with encouraging results, it also enables deferring surgical reintervention in the majority of patients.
No takes yet. Share an insight, caveat, or question.
Fiszer et al. (2017) conducted an observational in Right ventricular outflow tract dysfunction (n=46). Transcutaneous pulmonary valve replacement vs. Pre-procedure baseline was evaluated on RVOT systolic gradient (mm Hg) (p=<0.001). Transcutaneous pulmonary valve replacement significantly reduced the right ventricular outflow tract systolic gradient from 35.3 mm Hg to 13.5 mm Hg and restored valve competence.
Synapse has enriched 10 related papers. Consider them for comparative context: